Limitations and obstacles of the spontaneous adverse drugs reactions reporting: Two "challenging" case reports

Journal of Pharmacology and Pharmacotherapeutics

Volumn 4, Issue SUPPL.1, 2013, Pages

  Palleria, Caterina ^a,b   Leporini, Christian ^a,b   Chimirri, Serafina ^a,b   Marrazzo, Giuseppina ^a,b   Sacchetta, Sabrina ^a,b   Bruno, Lucrezia ^a,b   Lista, Rosaria ^c   Staltari, Orietta ^a,b   Scuteri, Antonio ^a,b   Scicchitano, Francesca ^a,b   Russo, Emilio ^a,b  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b Policlinico Mater Domini   (Italy)

^c Farmacovigilanza Territorio Paola ^*  (Italy)

Author keywords

Asthma exacerbation; bimatoprost; cystitis; tizanidine; under reporting

Indexed keywords

ADRENALIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BIMATOPROST; CIPROFLOXACIN; CORTICOSTEROID; NAVIZAN; OXYGEN; RISEDRONIC ACID; TIZANIDINE; UNCLASSIFIED DRUG;

ACUTE RESPIRATORY FAILURE; ADULT; ASTHMA; CASE REPORT; CAUSAL ATTRIBUTION; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FEMALE; HEMATURIA; HEMORRHAGIC CYSTITIS; HUMAN; LOW BACK PAIN; MIDDLE AGED; OPEN ANGLE GLAUCOMA; OSTEOPOROSIS; PATIENT SAFETY; REVIEW; STOMACH CARCINOMA;

EID: 84889595559     PISSN: 0976500X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0976-500X.120955     Document Type: Review

References (43)

1. Edwards IR, Aronson JK. Adverse drug reactions: Definitions, diagnosis, and management. Lancet 2000;356:1255-9.
2. Mazzitello C, Esposito S, De Francesco AE, Capuano A, Russo E, De Sarro G. Pharmacovigilance in Italy: An overview. J Pharmacol Pharmacother 2013 in press.
3. World Health Organization. Safety of medicines. A Guide to Detecting and Reporting Adverse Drug Reactions. Geneva, Switzerland: World Health Organization; 2002.
4. Oshikoya KA, Awobusuyi JO. Perceptions of doctors to adverse drug reaction reporting in a teaching hospital in Lagos, Nigeria. BMC Clin Pharmacol 2009;9:14.
5. Vallano A, Cereza G, Pedròs C, Agustí A, Danés I, Aguilera C, et al. Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital. Br J Clin Pharmacol 2005;60:653-8.
6. Biagi C, Montanaro N, Buccellato E, Roberto G, Vaccheri A, Motola D. Underreporting in pharmacovigilance: An intervention for ItalianGPs (Emilia-Romagna region). Eur J Clin Pharmacol 2013;69:237-44.
7. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: A systematic review. Drug Saf 2006;29:385-96.
8. Inman WH. Attitudes to adverse drug reaction reporting. Br J Clin Pharmacol 1996;41:434-5.
9. Herdeiro MT, Figueiras A, Polónia J, Gestal-Otero JJ. Physicians' attitudes and adverse drug reaction reporting: A case-control study in Portugal. Drug Saf 2005;28:825-33.
10. De Sarro GB, De Sarro A. Antagonists of adenosine and alpha-2-adrenoceptors reverse the anticonvulsant effects of tizanidine in DBA/2 mice. Neuropharmacology 1989;28:211-5.
11. Henney HR 3rd, Runyan JD. A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients. Int J Clin Pract 2008;62:314-24.
12. Curran MP. Bimatoprost: A review of its use in open-angle glaucoma and ocular hypertension. Drugs Aging 2009;26:1049-71.
13. Patil AJ, Vajaranant TS, Edward DP. Bimatoprost-a review. Expert Opin Pharmacother 2009;10:2759-68.
14. Freitag FG. Preventative treatment for migraine and tension-type headaches: Do drugs having effects on muscle spasm and tone have a role? CNS Drugs 2003;1:373-81.
15. Bou Khalil R. Tizanidine for alcohol withdrawal treatment. Med Hypotheses 2011;77:548-9.
16. Kamen L, Henney HR 3rd, Runyan JD. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. Curr Med Res Opin 2008;24:425-39.
17. Simon O, Yelnik AP. Managing spasticity with drugs. Eur J Phys Rehabil Med 2010;46:401-10.
18. Johnson TR, Tobias JD. Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension. J Child Neurol 2000;15:818-9.
19. Publow SW, Branam DL. Hypotension and bradycardia associated with concomitant tizanidine and lisinopril therapy. Am J Health Syst Pharm 2010;67:1606-10.
20. Spiller HA, Bosse GM, Adamson LA. Retrospective review of Tizanidine (Zanaflex) overdose. J Toxicol Clin Toxicol 2004;42:593-6.
21. Drug Information Online. Drugs.com. Zanaflex Side Effects. Copyright © 2000-2013 Drugs.com. [updated 2013 May 17]. Available from: http://www. drugs.com/sfx/zanaflex-side-effects.html [Last accessed on 2013 Jul 29].
22. Momo K, Homma M, Kohda Y, Ohkoshi N, Yoshizawa T, Tamaoka A. Drug interaction of tizanidine and ciprofloxacin: Case report. Clin Pharmacol Ther 2006;80:717-9.
23. Roberts RC, Part NJ, Pokorny R, Muir C, Leslie GC, Emre M. Pharmacokinetics and pharmacodynamics of tizanidine. Neurology 1994;44(11 Suppl 9):S29-31.
24. Fanos V, Mormile R, Benini D, Vecchini S, Cuzzolin L. Flurithromycininduced acute interstitial nephritis. Pediatr Infect Dis J 2000;19:366-7.
25. Henao J, Hisamuddin I, Nzerue CM, Vasandani G, Hewan-Lowe K. Celecoxib-induced acute interstitial nephritis. Am J Kidney Dis 2002;39:1313-7.
26. Kleinknecht D, Landais P, Goldfarb B. Acute renal failure associated with drugs or iodinated contrast media. Results of a cooperative multicentric study by the Nephrology Society]. Nephrologie 1986;7:41-6.
27. Available from: http://www.agenziafarmaco.gov.it/en/content/post- marketing-surveillance. Rete Nazionale di Farmacovigilanza (Pharmacovigilance National Network; last accessed 15 July 2013).
28. Dams I, Wasyluk J, Prost M, Kutner A. Therapeutic uses of prostaglandin F2 analogues in ocular disease and novel synthetic strategies. Prostaglandins Other Lipid Mediat 2013;104-105:109-21.
29. Chae B, Cakiner-Egilmez T, Desai M. Glaucoma medications. Insight 2013;38:5-9.
30. Takano N, Tsuruma K, Ohno Y, Shimazawa M, Hara H. Bimatoprost protects retinal neuronal damage via Akt pathway. Eur J Pharmacol. 2013;702:56-61.
31. Tsumura T, Yoshikawa K, Suzumura H, Kimura T, Sasaki S, Kimura I, et al. Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. Clin Ophthalmol 2012;6:1547-52.
32. Beers MH, Berkow R. The merck manual of diagnosis and therapy. 17th ed. New Jersey: Whitehouse Station; 1999. p. 556-68, 1053-4.
33. Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, et al, editors. Harrison's Principles of Internal Medicine. 14th ed. New York: McGraw-Hill; 1998. p.1419-23.
34. Sokolova TS, Reznik IB, Markov CM. Role of prostaglandins in the pathogenesis of bronchial asthma in children and possibilities in therapeutic treatment. Allergol Immunopathol (Madr) 1984;12:267-73.
35. Szmidt M, Wasiak W. The influence of misoprostol (synthetic analogue of prostaglandin E1) on aspirin-induced bronchoconstriction in aspirinsensitive asthma. J Investig Allergol ClinImmunol 1996;6:121-5.
36. Kelsen SG, D'Alonzo GE. Acute and Chronic Effects of Misoprostol in the Control of Asthma: A Pilot Study in Five Subjects. Am J Ther 1995;2:793-8.
37. Hofmeyr GJ, Gülmezoglu AM, Pileggi C. Vaginal misoprostol for cervical ripening and induction of labour. Cochrane Database Syst Rev 2010;10:CD000941.
38. Bygdeman M. Prostaglandin analogues and their uses. Baillieres Clin Obstet Gynaecol 1992;6:893-903.
39. Thomson PDR. Physician's desk reference, 57th ed. Montvale (NJ); 2003. p. 1347-9.
40. Dombrowski MP. Asthma and pregnancy. Obstet Gynecol 2006;108:667-81.
41. Bianco MP. Perspectives in the treatment of reversible airway obstruction. Respiration 1986;50:131-6.
42. Wasiak W, Szmidt M. A six week double blind, placebo controlled, crossover study of the effect of misoprostol in the treatment of aspirin sensitive asthma. Thorax 1999;54:900-4.
43. Towers CV, Briggs GG, Rojas JA. The use of prostaglandin E2 in pregnant patients with asthma. Am J Obstet Gynecol 2004;190:1777-80.